Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Latest News

February 6, 2023 • 4:00pm EST

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read Press Release View All News

January 25, 2023 • 1:00pm EST

Aurinia Announces PTAB Has Terminated Inter Partes Review

Read Press Release View All News

January 24, 2023 • 4:00pm EST

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

Read Press Release View All News